Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
MangoRx hits back at Eli Lilly’s weight loss drug copycat claims
MangoRx was responding to Eli Lily after the drugmaker sued it and two other medical spas and online vendors earlier this week for selling products claiming to contain tirzepatide
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering counterfeit versions of Zepbound and Mounjaro
Mangoceuticals ‘refutes’ claims by Eli Lilly regarding sale of tirzepatide
Mangoceuticals (MGRX) learned earlier this morning that Eli Lilly (LLY) has made certain public claims alleging, and has stated that it
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs
Mangoceuticals Inc. (MGRX) announced that Eli Lilly has made public allegations and filed a lawsuit against the company, claiming
Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit
Mangoceuticals (MGRX) said it strongly refutes claims made in a lawsuit filed by Eli Lilly (LLY) over a compounded version of Lilly’s weight-loss drug tirzepatide. Read more here.
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
UK's NHS to block Eli Lilly's Alzheimer's drug on Wednesday, Telegraph reports
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...
STAT23h
Senators demand answers on telehealth platforms from Pfizer and Eli Lilly
Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...
Medpage Today on MSN18h
Why Hospital Gowns Are Ugly; Mass Food Poisoning in Maryland; Eli Lilly Files Suit
In Washington state, four agricultural workers tested presumptively positive for avian influenza after contact with infected ...
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Spirit Airlines, Eli Lilly, Humana-Cigna: 3 Stories In Focus
Spirit Airlines (SAVE) extends its debt refinancing deadline with the US Bank National Association, sending the stock soaring ...
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
STAT18h
Pharmalittle: We’re reading about a probe of Pfizer and Lilly telehealth, pharma exec donations, and more
Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...